| Bioactivity | Cinanserin (SQ 10643) is a potent and selective 5-HT2 antagonist with Ki values of 41, 3500 nM for 5-HT2, 5-HT1, respectively. Cinanserin also is a SARS-CoV 3CLpro inhibitor with an KD value of 49.4, 18.2 µM for SARS-CoV 3CLpro, HCoV-229E 3CLpro, respectively. Cinanserin reduces systemic burn edema levels[1][2][3]. |
| In Vivo | Cinanserin (5 mg/kg; i.v.) 治疗可显著降低全身烧伤水肿水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1166-34-3 |
| Formula | C20H24N2OS |
| Molar Mass | 340.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hernekamp JF, et al. Cinanserin reduces plasma extravasation after burn plasma transfer in rats. Burns. 2013 Sep;39(6):1226-33. [2]. Chen L, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol. 2005 Jun;79(11):7095-103. [3]. Leysen, J. E., et al. Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors. Life Sciences, 1981, 28(9), 1015-1022. |